Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
progression-free survival
from beginning treatment to progressive disease or the last follow-up
2-year
No
Ming Chen, M.D.
Principal Investigator
Zhejiang Cancer Hospital
China: Ethics Committee
[2012]-10-24
NCT01733589
November 2012
May 2014
Name | Location |
---|